BML Capital Management’s Turnstone Biologics TSBX Stock Holding History

BML Capital Management’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,103,386	Closed	-$396K	–	26
2025 Q2	$396K	Hold	1,103,386	–	–	0.3%	21
2025 Q1	$452K	Buy	+1,103,386	New	+$470K	0.37%	21

BML Capital Management's TSBX Position: Q3 2025 in Review

BML Capital Management sold out of Turnstone Biologics (TSBX) in Q3 2025, closing a stake of 1,103,386 shares — an estimated $396K sold.

BML Capital Management first reported a position in TSBX in Q1 2025 and held it in 2 quarters. The position peaked at $452K in Q1 2025. 1 fund tracked by Wall St. Rank holds TSBX as of Q3 2025.

BML Capital Management reported no remaining Turnstone Biologics position as of Q3 2025 after selling out during the quarter.
BML Capital Management sold 1,103,386 Turnstone Biologics shares in Q3 2025, an estimated $396K.
BML Capital Management first reported a position in Turnstone Biologics in Q1 2025 and held it in 2 quarters.
BML Capital Management's Turnstone Biologics position peaked at $452K in Q1 2025.
1 fund tracked by Wall St. Rank held Turnstone Biologics as of Q3 2025.

Based on BML Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.